NEVAKAR INJECTABLES - Key Persons

Job Titles:

• Chairman
• Member of the Senior Management Team

George Zorich has been in pharmaceutical fields for over 40 years, including Big Pharma, Biotech, Generics, Distribution companies and Start-ups. Most recently, Mr. Zorich was on the board of Custopharm which sold to Hikma in 2022 and is currently on the board of Nevakar, Inc. Prior to that he was CEO of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich's ataxia using DNA based therapies, which was sold to PTC Therapeutics. He was also the president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products, leading to the sale to Mylan Pharmaceuticals for $550MM in late 2010. Before that, Mr. Zorich was president of Sabex-USA leading to its sale to Sandoz for $480MM in 2004, where he then headed up the Sandoz US injectable business. Before that, he was president of GIV, which at that time was the largest distributor of vaccines to physician offices, leading to the sale to Henry Schein, the multibillion-dollar distributor. Mr. Zorich has also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and began at Eli Lilly and Company. Mr. Zorich received his pharmacy degree from the University of Wisconsin.

Job Titles:

• Member of the Senior Management Team
• Senior Vice President, Program Management and Regulatory Affairs

Job Titles:

• Chief Scientific Officer
• Member of the Senior Management Team

Job Titles:

• Chief Executive Officer
• Member of the Senior Management Team
• Pharmacist With a Master

Mr. Ramanathan is a pharmacist with a Master's degree in Business Administration. He brings to Nevakar over 20 years of experience in the pharmaceutical industry including R&D, process development, and operations. As Chief Executive Officer, Mr. Ramanathan leads all aspects of the company. Before his promotion to CEO, he was President and Chief Operating Officer at Nevakar. Prior to joining Nevakar, Mr. Ramanathan was Chief Operating Officer of InnoPharma, Inc. and stayed on as Executive Director, Operating Officer after its acquisition by Pfizer, Inc. Before this, he worked at Cardinal Health, Alpharma, Inhale Therapeutics (now Nektar Therapeutics), and Roche Vitamins Inc. Mr. Ramanathan earned his MBA from NYU Stern School of Business and an MS in Pharmaceutical Sciences from the University of Mississippi.